Form DEF 14A NEUMORA THERAPEUTICS For: 17 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics Inc stock price live, this page displays NASDAQ NMRA stock exchange data. View the NMRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neumora Therapeutics Inc real time stock price chart below.
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 2.31.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock symbol for Neumora Therapeutics Inc is "NMRA."
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 2.31.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock symbol for Neumora Therapeutics Inc is "NMRA."
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.29
2.48
52 wk Range
0.61
3.65
Unusual Pre-Market activity
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.292.48
52 wk Range
0.613.65
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NMRA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
8.91
Upside
+285.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 13D/A Neumora Therapeutics For: 1 April
- Investing.com
- Form DEF 14A NEUMORA THERAPEUTICS For: 17 April
- Investing.com
- Form 13D/A Neumora Therapeutics For: 1 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
7 Buy
1 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.91
(+285.61% Upside)
Neumora Therapeutics Inc SWOT Analysis
Navacaprant Setback | Neumora's lead drug for major depressive disorder faces challenges after KOSTAL-1 trial failure, prompting reevaluation of its $2.2 billion peak sales forecast |
Pipeline Potential | Explore Neumora's diverse neuroscience portfolio targeting bipolar depression, schizophrenia, and Alzheimer's-related agitation, offering multiple growth avenues |
Financial Health | Despite strong cash reserves, Neumora grapples with negative free cash flow and high debt, presenting a complex financial picture for investors |
Market Outlook | Analysts maintain cautious optimism with price targets ranging from $7 to $29, reflecting the uncertain yet potentially lucrative neuroscience market |
Neumora Therapeutics Inc Earnings Call Summary for Q4/2025
- Neumora reported Q4 2025 EPS of -$0.35, beating forecast of -$0.47 by 25.53%; stock fell 7.73% to $2.15 in premarket trading.
- Company maintains $182.5M cash position, extending runway into Q3 2027; operating expenses held flat year-over-year.
- NMRA-511 showed promising Phase 1B results; Phase II study planned for Q1 2027 as company prioritizes near-term catalysts.
- NMRA-215 clinical entry delayed, prompting capital reallocation to other pipeline programs; net loss remained comparable to 2024.
Last Updated: 03/30/2026, 08:56 PM
Read Full TranscriptEarnings
Latest Release
Mar 30, 2026
EPS / Forecast
-0.35 / -0.47
Revenue / Forecast
-- / --
Compare NMRA to Peers and Sector
Metrics to compare | NMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −8.5x | −0.5x | |
PEG Ratio | −0.35 | 0.06 | 0.00 | |
Price/Book | 4.1x | 3.6x | 2.6x | |
Price / LTM Sales | - | 4.9x | 3.3x | |
Upside (Analyst Target) | 219.2% | 78.4% | 47.1% | |
Fair Value Upside | Unlock | 6.4% | 6.2% | Unlock |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Neumora Therapeutics (NMRA) Stock Price Today?
The Neumora Therapeutics stock price today is 2.31 USD.
What Stock Exchange Does Neumora Therapeutics Trade On?
Neumora Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Neumora Therapeutics?
The stock symbol for Neumora Therapeutics is "NMRA."
What Is the Neumora Therapeutics Market Cap?
As of today, Neumora Therapeutics market cap is 422.01M USD.
What Is Neumora Therapeutics's Earnings Per Share (TTM)?
The Neumora Therapeutics EPS (TTM) is -1.45.
When Is the Next Neumora Therapeutics Earnings Date?
Neumora Therapeutics will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is NMRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Neumora Therapeutics Stock Split?
Neumora Therapeutics has split 0 times.
How Many Employees Does Neumora Therapeutics Have?
Neumora Therapeutics has 96 employees.
What is the current trading status of Neumora Therapeutics (NMRA)?
As of May 05, 2026, Neumora Therapeutics (NMRA) is trading at a price of 2.31 USD, with a previous close of 2.31 USD. The stock has fluctuated within a day range of 2.29 USD to 2.48 USD, while its 52-week range spans from 0.61 USD to 3.65 USD.
What Is Neumora Therapeutics (NMRA) Price Target According to Analysts?
The average 12-month price target for Neumora Therapeutics is 8.91 USD, with a high estimate of 18 USD and a low estimate of 3 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +285.61% Upside potential.
What Is the NMRA Premarket Price?
NMRA's last pre-market stock price is 2.47 USD. The pre-market share volume is 10,000.00, and the stock has decreased by 0.16, or 6.93%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.